Baseline characteristics of patients with RP during initial CMR
| N=200 | |
| Age, years | 46±14 |
| Female gender, n (%) | 104 (52) |
| Chest pain, n (%) | 150 (75) |
| NYHA class (II–IV), n (%) | 103 (52) |
| Duration since initial diagnosis of pericarditis, months | 15 (6–116) |
| Number of recurrences before initial CMR | 4 (2–6) |
| Idiopathic aetiology of pericarditis, n (%) | 94 (47) |
| Hypertension, n (%) | 37 (19) |
| Diabetes mellitus, n (%) | 16 (8) |
| Atrial fibrillation, n (%) | 22 (11) |
| Quantitative DHE, cm3 | 50±36 |
| Qualitative DHE > none | 145 (72.5) |
| Pericardial thickness BB, mm | 2.1±0.7 |
| Anti-inflammatory medications before initial CMR | |
| NSAIDs, n (%) | 106 (53) |
| Colchicine, n (%) | 142 (71) |
| Prednisone, n (%) | 98 (49) |
| DMARDs/biologicals, n (%) | 18 (9) |
Values are mean±SD, median (IQR) or n (%).
BB, black blood; CMRI, cardiovascular MRI; DHE, delayed hyperenhancement; DMARDs, disease-modifying antirheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs; NYHA, New York Heart Association; RP, recurrent pericarditis.